Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

The Chk1-Cdc25C regulation is involved in sensitizing A253 cells to a novel topoisomerase I inhibitor BNP1350 by bax gene transfer

Abstract

Promotion of apoptosis may potentiate the sensitivity of tumor cells to chemotherapeutic agents, thus improving the efficacy of cancer treatment. The transfection of the proapoptotic bax gene, which results in the overexpression of bax protein, augments the growth inhibition of A253 cells by BNP1350. Increased drug response was associated with the induction of DNA fragmentation in the size of 30–200 Kb, generating a cleaved fragment of 18 kDa from full-length 21 kDa bax and the cleavage of PARP. A253/vec cells treated with 0.07 μM(IC50) of BNP1350 accumulated in G2 phase at 24 h after drug removal. In contrast, A253/Bax cells treated with an equimolar concentration of BNP1350 primarily displayed a G1 phase accumulation with a concurrent decrease in G2 phase. Certain cell cycle regulatory protein expression and activities were altered following drug exposure in both cell lines under similar conditions. Cdk2- and cdc2-associated H1 kinase activities were markedly increased in the A253/Bax cell line with marginal increased activity in the A253/vec cell line. A chk1 activity assay was performed with GST-cdc25C (200–256) or GST-cdc25CS216A (200–256) fusion proteins as the substrate. Increased chk1 activity was observed in the A253/vec cell line, with little change in the A253/Bax cell line, when exposed to equimolar concentrations of BNP1350 (0.07 μM). A Western blot of immunoprecipitated chk1 indicated that increased chk1 phosphorylation following DNA damage induced by BNP1350 was accompanied by the observed G2 accumulation in the A253/vec cell line, while only a slight increase in chk1 phosphorylation was seen in the A253/Bax cell line. A decreased expression of cdc25C was observed in the BNP1350-treated A253/Bax cells, but not in the A253/vec cell line. Following exposure to BNP1350, increased binding of 14-3-3 proteins to chk1 occurred in both cell lines, with more being observed in the A253/vec cell line. The data have shown that inhibition of the chk1 pathway accompanied by the abrogation of G2 arrest is involved in sensitizing A253 cells to BNP1350 by bax gene transfer. These findings suggest that bax gene transfer sensitizes A253 cells to BNP1350 through apoptosis promoting and G2/M DNA damage checkpoint regulatory pathways.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

Abbreviations

Topo I:

topoisomerase I

SRB:

sulforhodamine B, cdk, cyclin-dependent kinase

chk:

checkpoint kinase

GST:

glutathione S-transferase

PFGE:

pulsed-field gel electrophoresis

References

  • al-Khodairy F, Fotou E, Sheldrick KS, Griffiths DJ, Lehmann AR, Carr AM . 1994 Mol. Biol. Cell 5: 147–160

  • Arafat WO, Gomez-Navarro J, Xiang J, Barnes MN, Mahasreshti P, Alvarez RD, Siegal GP, Badib AO, Buchsbaum D, Curiel DT, Stackhouse MA . 2000 Mol. Ther. 1: 545–554

  • Brady HJ, Gil-Gomez G, Kirberg J, Berns AJ . 1996 EMBO J. 15: 6991–7001

  • Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B . 2000 Genes Dev. 14: 1584–1588

  • Chen L, Liu TH, Walworth NC . 1999 Genes Dev. 13: 675–685

  • Coll JL, Negoescu A, Louis N, Sachs L, Tenaud C, Girardot V, Demeinex B, Brambilla E, Brambilla C, Favrot M . 1998 Hum. Gene. Ther. 9: 2063–2074

  • Collins JA, Schandi CA, Young KK, Vesely J, Willingham MC . 1997 J. Histochem. Cytochem. 45: 923–934

  • Dubrez L, Goldwasser F, Genne P, Pommier Y, Solary E . 1995 Leukemia 9: 1013–1024

  • Elledge SJ . 1996 Science (Washington DC) 274: 1664–1672

  • Gil-Gomez G, Berns A, Brady HJ . 1998 EMBO J. 17: 7209–7218

  • Giaccia AJ, Shieh J, Cholon A, Brown JM . 1991 Mutat. Res. 263: 69–75

  • Goldwasser F, Shimizu T, Jackman J, Hoki Y, O'Connor PM, Kohn KW, Pommier Y . 1996 Cancer Res. 56: 4430–4437

  • Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, Piwnica-Worms H . 2000 J. Biol. Chem. 275: 5600–5605

  • Guo B, Yin MB, Toth K, Cao S, Azrak RG, Rustum YM . 1999 Oncol. Res. 11: 91–99

  • Guo B, Cao S, Toth K, Azrak RG, Rustum YM . 2000 Clin. Cancer Res. 6: 718–724

  • Hakem A, Sasaki T, Kozieradzki I, Penninger JM . 1999 J. Exp. Med. 189: 957–968

  • Hsu SL, Yin SC, Liu MC, Reichert U, Ho WL . 1999 Exp. Cell Res. 252: 332–341

  • Huang DC, O'Reilly LA, Strasser A, Cory S . 1997 EMBO J. 16: 4628–4638

  • Jackson JR, Gilmartin A, Imburgia C, Winkler JD, Marshall LA, Roshak A . 2000 Cancer Res. 60: 566–572

  • Jacotot E, Ferri KF, Kroemer G . 2000 Pathol. Biol. 48: 271–279

  • Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC . 1995 Cancer Res. 55: 4471–4478

  • Laemmli UK . 1970 Nature (Lond.) 227: 680–685

  • Lind EF, Wayne J, Wang QZ, Staeva T, Stolzer A, Petrie HT . 1999 J. Immunol. 162: 5374–5379

  • Linette GP, Li Y, Roth K, Korsmeyer SJ . 1996 Proc. Natl. Acad. Sci. USA 93: 9545–9552

  • Lopez-Girona A, Furnari B, Mondesert O, Russell P . 1999 Nature (Lond.) 397: 172–175

  • McPake CR, Tillman DM, Poquette CA, George EO, Houghton JA, Harris LC . 1998 Oncol. Res. 10: 235–244

  • Oberhammer F, Wilson JM, Dive C, Morris ID, Hickman JA, Wakeling AE, Walker PR, Sikorska M . 1993 EMBO J. 12: 3679–3684

  • O'Connell MJ, Raleigh JM, Verkade HM, Nurse P . 1997 EMBO J. 16: 545–554

  • Ohi R, Gould KL . 1999 Curr. Opin. Cell Biol. 11: 267–273

  • Panadero A, Yin MB, Voigt W, Rustum YM . 1995 Oncol. Res. 7: 73–81

  • Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H . 1997 Science (Washington DC) 277: 1501–1505

  • Peng CY, Graves PR, Ogg S, Thoma RS, Byrnes MJ, Wu Z, Stephenson MT, Piwnica-Worms H . 1998 Cell Growth Differ. 9: 197–208

  • Raleigh JM, O'Connell MJ . 2000 J. Cell Sci. 113: 1727–1736

  • Roshak A, Gilmartin A, Imburgia C, Marshall LA, Jackson JR . 1999 Proc. Am. Assoc. Cancer Res. 40: 413–414

  • Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, Colombo MP, Gramegna M, Croce CM, Pierotti MA, Sozzi G . 1999 Proc. Natl. Acad. Sci. USA 96: 8489–8492

  • Schwartz DC, Cantor CR . 1984 Cell 37: 67–75

  • Shinoura N, Saito K, Yoshida Y, Hashimoto M, Asai A, Kirino T, Hamada H . 2000 Cancer Gene Ther. 7: 739–748

  • Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR . 1990 J. Natl. Cancer Inst. 82: 1107–1112

  • Strobel T, Swanson L, Korsmeyer S, Cannistra SA . 1996 Proc. Natl. Acad. Sci. USA. 93: 14094–14099

  • Strobel T, Kraeft SK, Chen LB, Cannistra SA . 1998 Cancer Res. 58: 4776–4781

  • Sugimoto C, Fujieda S, Seki M, Sunaga H, Fan GK, Tsuzuki H, Borner C, Saito H, Matsukawa S . 1999 Int. J. Cancer 82: 860–867

  • Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA . 1998 J. Clin. Oncol. 16: 2583–2590

  • Tsai LH, Takahashi T, Caviness Jr VS, Harlow E . 1993 Development 119: 1029–1040

  • Vogelbaum MA, Tong JX, Higashikubo R, Gutmann DH, Rich KM . 1998 J. Neurosurg. 88: 99–105

  • Walworth N, Davey S, Beach D . 1993 Nature (Lond.) 363: 368–371

  • Walworth NC, Bernards R . 1996 Science (Washington DC) 271: 353–356

  • Wan S, Capasso H, Walworth NC . 1999 Yeast 15: 821–828

  • Xiang J, Chao DT, Korsmeyer SJ . 1996 Proc. Natl. Acad. Sci. USA 93: 14559–14563

  • Xiang J, Gomez-Navarro J, Arafat W, Liu B, Barker SD, Alvarez RD, Siegal GP, Curiel DT . 2000 J. Gene Med. 2: 97–106

  • Yin MB, Toth K, Cao S, Guo B, Frank C, Slocum HK, Rustum YM . 1999 Int. J. Cancer 83: 341–348

  • Yin MB, Guo B, Panadero A, Frank C, Wrzosek C, Slocum HK, Rustum YM . 1999 Exp. Cell Res. 247: 189–199

  • Yin MB, Guo B, Vanhoefer U, Azrak RG, Minderman H, Frank C, Wrzosek C, Slocum HK, Rustum YM . 2000 Mol. Pharmacol. 57: 453–459

Download references

Acknowledgements

We are grateful to Yolanda Sanchez for providing us with GST-cdc25C (200–256) and GST-cdc25CS216A (200–256). We also thank Geri Wagner for her secretarial assistance and BioNumerik Pharmaceuticals Inc. for providing us with BNP1350. This work was supported in part by project grant CA 65761 and a Comprehensive Cancer Center Support Grant CA 16056 from the National Cancer Institute, Bethesda, MD. G Hapke, was supported by grant HA3116/1-1 from the Deutsche Forschungsgemeinschaft, Bonn, Germany.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Youcef M Rustum.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yin, Mb., Hapke, G., Guo, B. et al. The Chk1-Cdc25C regulation is involved in sensitizing A253 cells to a novel topoisomerase I inhibitor BNP1350 by bax gene transfer. Oncogene 20, 5249–5257 (2001). https://doi.org/10.1038/sj.onc.1204686

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204686

Keywords

This article is cited by

Search

Quick links